You are using an outdated browser. Please upgrade your browser to improve your experience and security.

Synergistic combination for potent delivery1,2

Based on animal studiesa

Release of drugs from VYXEOS liposome

Increased activity vs free drug

The synergistic 1:5 molar ratio of daunorubicin and cytarabine has been shown to enhance the killing of leukemia cells in vitro and in murine models1

Leukemia cell uptake with VYXEOS

Greater leukemia cell uptake

VYXEOS liposomes enter the bone marrow and are preferentially taken up by leukemia cells to a greater extent than by normal bone marrow cells in a murine model1,3

  • Their unique composition allows the negatively charged VYXEOS liposomes to interact with receptors that are overexpressed by leukemic cells compared to the expression by normal bone marrow cells3,4

Based on pharmacokinetic Phase 1 trial data…

Cross-section of bone marrow with VYXEOS

Prolonged delivery

The longer half-life of VYXEOS resulted in greater drug exposure within the plasma and bone marrow than traditional chemotherapy1,5

  • Estimated median half-life of daunorubicin was 32 hours with VYXEOS vs 19 hours as free drug1,6
  • Estimated median half-life of cytarabine was 40 hours with VYXEOS vs approximately 1 to 3 hours as free drug1,7

aThe clinical relevance of this is unknown.

INDICATION

VYXEOS (daunorubicin and cytarabine) liposome for injection 44 mg/100 mg is indicated for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

IMPORTANT SAFETY INFORMATION

INDICATION

VYXEOS (daunorubicin and cytarabine) liposome for injection 44 mg/100 mg is indicated for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

Important Safety Information

WARNING: DO NOT INTERCHANGE WITH OTHER DAUNORUBICIN AND/OR CYTARABINE-CONTAINING PRODUCTS

VYXEOS has different dosage recommendations than daunorubicin hydrochloride injection, cytarabine injection, daunorubicin citrate liposome injection, and cytarabine liposome injection. Verify drug name and dose prior to preparation and administration to avoid dosing errors.